
Immunohistochemical Expression and Distribution of VEGFR-3 in Malignant Mesothelioma
Source: PubMed.Com
One of the most common research programs in the study of malignant mesothelioma is the search for biomarkers that improve upon the ability of current methodologies to diagnosis mesothelioma. The study that is referenced here looked at the expression of VEGFR-3 (vascular endothelial growth factor receptor-3) in patients with mesothelioma generally and its expression in subtypes of the disease. The population sample included 29 mesothelioma cases and 5 metastatic carcinomas. None of the metastatic carcinoma patients showed VEGFR-3 expression, while the majority of mesothelioma patients did. This expression carried through to all subtypes of the disease. The study concluded that VEGFR-3 expression is an important avenue of further research.
Mike is a licensed attorney and the former editor of North Carolina Lawyers Weekly and South Carolina Lawyers Weekly. He has contributed numerous articles to the North Carolina State Bar Journal and is a co-author of Capital Lawyers, a history of the Wake County (NC) Bar.
Gregory Froom is a licensed North Carolina attorney and the former editor of North Carolina Lawyers Weekly and South Carolina Lawyers Weekly.